By Marie Rosenthal, MS
ViiV Healthcare announced the start of HPTN 084, a phase 3 study to evaluate long-acting cabotegravir for the prevention of HIV infection in sexually active women. The study will compare injections of cabotegravir given every two months and daily oral pre-exposure prophylaxis (PrEP) with emtricitabine–tenofovir disoproxil fumarate (Truvada, Gilead Sciences).
The trial seeks to enroll 3,200 women, 18 to 45 years of age, from sub-Saharan African countries and is being